Stimulant use in patients with sturge-weber syndrome: Safety and efficacy

Eboni I. Lance, Kira E. Lanier, Theodore A Zabel, Anne Marie Spalding Comi

Research output: Contribution to journalArticle

Abstract

Background Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome.

Methods The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy.

Results All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit.

Conclusions This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndrome patients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndrome children with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.

Original languageEnglish (US)
Pages (from-to)675-680
Number of pages6
JournalPediatric Neurology
Volume51
Issue number5
DOIs
StatePublished - Nov 1 2014

Fingerprint

Sturge-Weber Syndrome
Safety
Vital Signs
Headache
Eye Abnormalities
Databases
Paresis
Appetite
Wine
Attention Deficit Disorder with Hyperactivity
Hemangioma
Sample Size
Blood Vessels
Comorbidity
Epilepsy
Blood Pressure
Weights and Measures
Brain
Growth
Research

Keywords

  • ADHD
  • neurocutaneous syndromes
  • stimulant medication
  • Sturge Weber syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Stimulant use in patients with sturge-weber syndrome : Safety and efficacy. / Lance, Eboni I.; Lanier, Kira E.; Zabel, Theodore A; Comi, Anne Marie Spalding.

In: Pediatric Neurology, Vol. 51, No. 5, 01.11.2014, p. 675-680.

Research output: Contribution to journalArticle

@article{fcc9c5cddaa445d8bbb1f79d85c85678,
title = "Stimulant use in patients with sturge-weber syndrome: Safety and efficacy",
abstract = "Background Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome.Methods The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy.Results All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit.Conclusions This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndrome patients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndrome children with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.",
keywords = "ADHD, neurocutaneous syndromes, stimulant medication, Sturge Weber syndrome",
author = "Lance, {Eboni I.} and Lanier, {Kira E.} and Zabel, {Theodore A} and Comi, {Anne Marie Spalding}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.pediatrneurol.2013.11.009",
language = "English (US)",
volume = "51",
pages = "675--680",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Stimulant use in patients with sturge-weber syndrome

T2 - Safety and efficacy

AU - Lance, Eboni I.

AU - Lanier, Kira E.

AU - Zabel, Theodore A

AU - Comi, Anne Marie Spalding

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome.Methods The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy.Results All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit.Conclusions This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndrome patients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndrome children with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.

AB - Background Sturge-Weber syndrome is characterized by a facial port-wine birthmark, vascular eye abnormalities, and a leptomeningeal angioma. Attention and behavioral issues are common in Sturge-Weber syndrome. However, literature evidence for stimulant treatment is minimal. This study evaluates stimulant medication safety and efficacy in individuals with Sturge-Weber syndrome.Methods The research database of the Hunter Nelson Sturge-Weber Center (n = 210 subjects in the database) was reviewed for stimulant use. Twelve patients (mean age 10.5 years, age range 4 to 21 years) on stimulants were seen between 2003 and 2012. A retrospective chart review obtained comorbid diagnoses, stimulant type and dosage, medication side effects, vital signs, and medication efficacy.Results All 12 patients had brain involvement (unilateral, nine; bilateral, three). Additional comorbidities included epilepsy (twelve), hemiparesis (eight), headaches (eight), and vision deficits (six). Eight patients reported side effects, primarily appetite suppression (four) and headaches (three). There were no statistically significant changes in weight or blood pressure 6 months after medication initiation. Medication efficacy was subjectively reported in 11 patients. Seven patients remained on stimulants at their most recent follow-up visit.Conclusions This study preliminarily evaluates stimulant medication use in a small group of Sturge-Weber syndrome patients. Stimulants were tolerated and effective in most subjects. Side effects were mostly minor and medication did not negatively affect growth or vital signs. Stimulant medication may be a safe and effective intervention for Sturge-Weber syndrome children with attention issues/attention deficit hyperactivity disorder. Further studies with larger sample sizes are needed.

KW - ADHD

KW - neurocutaneous syndromes

KW - stimulant medication

KW - Sturge Weber syndrome

UR - http://www.scopus.com/inward/record.url?scp=84908299550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908299550&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2013.11.009

DO - 10.1016/j.pediatrneurol.2013.11.009

M3 - Article

C2 - 25439578

AN - SCOPUS:84908299550

VL - 51

SP - 675

EP - 680

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 5

ER -